New Phase 1 clinical study designed to build on nonclinical evidence of anti-inflammatory signaling and potential disease-modifying effect of TRV045 in the treatment of epilepsy and other CNS disorders TRV045, a novel S1P receptor…
OLINVYK study demonstrated a statistically significant reduced impact on respiratory function compared to IV morphine, among elderly/overweight subjects OLINVYK oral presentation was selected as “Best of Abstracts: Clinical Science” at…
CHESTERBROOK, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders,…
Actor and Fashion Personality Oliver Trevena in the new Tudor Rose ad campaign by William Henry
Every piece in the Tudor Rose collection is handcrafted to the…
Caliwater cactus water beverage is now available at all Erewhon grocery market locations across California.
"We are so excited to finally be available at…
-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality ~12 days lower average hospital length of stay in patients treated…
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China CHESTERBROOK, Pa., July 08, 2021 (GLOBE…